Bifogade filer
CombiGene Q2 2021 EN
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Second quarter April - June 2021
• Net sales: 0 (0) TSEK.
• Other operating income: 839 (2161) TSEK.
• Profit after financial items: -15 402 (-4 389) TSEK.
• Earnings per share: -0.06 (-0.04) SEK.
Period January - June 2021
• Net sales: 0 (0) TSEK.
• Other operating income: 5 957 (6 219) TSEK.
• Profit after financial items: -26 258 (-12 055) TSEK.
• Earnings per share: SEK -0.11 (-0.11).
• Liquidity at the end of the period: 82 376 (18 026) TSEK.
• End-of-period equity/assets ratio: 97 (71) %.
Events during the period
• CombiGene completes a fully guaranteed rights issue providing the company with approximately SEK 75 million before issue costs.
• On May 25, 2021, CombiGene AB held its Annual General Meeting (AGM) in Lund. The AGM resolved all matters in accordance with the proposal of the Board of Directors and the Nomination Committee. The AGM resolved to re-elect Peter Nilsson, Bert Junno, Jonas Ekblom and Per Lundin as Board members and to elect Gunilla Lundmark as new member of the Board. Bert Junno was also re-elected Chairman of the Board. Mazars AB was re-elected as auditor. The AGM resolved, in accordance with the Nomination Committee’s proposal, on board fees and that auditor’s fees shall be paid in accordance with approved invoices. The AGM further resolved to merge the company’s shares, with twenty (20) existing shares being combined into one (1) new share (aggregation 1:20). The AGM also resolved to amend the Articles of Association in such a way that the Board of Directors shall have its registered office in Stockholm, instead of Lund, Skåne County.
• CombiGene and Neurochase initiated the work of optimizing the administration of CG01 in a preclinical study. The results of the study are expected to be completed in late summer 2021 and a positive outcome will mean that long-term studies in toxicology and biodistribution in large animals can start as planned.
• The plasmids to be used in the GMP production of CG01 have been manufactured and subjected to the usual quality assurance. The plasmids will be used as starting material for the GMP batch that will be used in the first clinical study scheduled to begin in 2022.
Events after the end of the period
• GMP production of CG01 for the first human study.
• CG01 gets patents in the U.S. and Russia.